Inbox Robot: Drug-Coated Heart Stents News http://www.inboxrobot.com/news/drug-eluting-coronary-stentsConstantly updated news and information about a variety of topics. CYPHER Sirolimus-eluting Coronary Stent Comparable To Bypass Surgery In Key Safety Measures In Patients With Diabetes And Multi-Vessel Disease http://www.inboxrobot.com/news.php?fid=186852606 7 Sep 2008 00:36 GMT ... intervention (PCI) with the CYPHER Sirolimus-eluting Coronary Stent was comparable to bypass surgery (coronary artery ... meeting. The CYPHER Stent is the only drug-eluting stent with such randomized clinical data indicating ... and bypass surgery in terms of death, heart attacks or stroke, the primary endpoints for ... Clinical Data Indicate that Percutaneous Coronary Intervention with the Cypher Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery http://www.inboxrobot.com/news.php?fid=186687077 5 Sep 2008 17:04 GMT ... Coronary Intervention with the Cypher Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery MUNICH--(BUSINESS WIRE)--Sep ... meeting. The CYPHER(R) Stent is the only drug-eluting stent with such randomized clinical data indicating ... and bypass surgery in terms of death, heart attacks or stroke, the primary endpoints for ... BIOSENSORS DES DEMONSTRATES EQUIVALENT SAFETY AND EFFICACY TO INDUSTRY LEADING DES IN FIRST 'REAL WORLD, ALL COMERS' CLINICAL STUDY http://www.inboxrobot.com/news.php?fid=186659988 5 Sep 2008 14:18 GMT ... BIG: SP) Today Announced That A Next-generation Drug-eluting Stent, Developed By Biosensors, Has Demonstrated Equal Safety ... Today At The 2008 European Society Of Cardiology Congress And Published Concurrently On-line By The ... The Role Played By Drug-Eluting Stents In Reducing Mortality In AMI http://www.inboxrobot.com/news.php?fid=186649677 5 Sep 2008 13:07 GMT ... The safety debate about drug-eluting stents (DES) is still ongoing. In these times ... inclusion criteria. For the first time, three drug eluting stents, namely Cypher, Taxus and Endeavor, were ... Boston Scientific reports positive data from Taxus Olympia registry http://www.inboxrobot.com/news.php?fid=186605170 5 Sep 2008 02:14 GMT ... Boston Scientific's second-generation Taxus Liberte paclitaxel-eluting coronary stent system in the treatment of patients with ... (56.5%), prior percutaneous coronary intervention (27.9%), prior myocardial infarction (34.1%), multiple stents (32.3%), and medically ... is consistent with safety data from other drug-eluting stent (DES) registries. In the more complex ... Bypass Surgery Better Than Stents, Study Concludes http://www.inboxrobot.com/news.php?fid=186604803 5 Sep 2008 02:13 GMT ... surgery and angioplasty have similar effects for heart patients with clogged arteries, the surgical procedure ... comparing Boston Scientific Corp.'s (BSX) Taxus Express drug-coated stents with bypass surgery. The findings, revealed at ... Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease http://www.inboxrobot.com/news.php?fid=186553523 4 Sep 2008 19:17 GMT ... Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key ... meeting. The CYPHER(R) Stent is the only drug-eluting stent with such randomized clinical data indicating ... and bypass surgery in terms of death, heart attacks or stroke, the primary endpoints for ... Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease Results C http://www.inboxrobot.com/news.php?fid=186546858 4 Sep 2008 18:29 GMT ... Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key ... meeting. The CYPHER(R) Stent is the only drug-eluting stent with such randomized clinical data indicating ... and bypass surgery in terms of death, heart attacks or stroke, the primary endpoints for ... Drug eluting stents: New elements in the debate http://www.inboxrobot.com/news.php?fid=186508399 4 Sep 2008 14:30 GMT ... in Barcelona questioned the long-term safety of drug eluting stents (DES) and sparked intense discussion. The dark ... and regulatory bodies gathered at the European Heart House with studies and registries presenting data ... New generation drug-eluting stent demonstrates equivalent efficacy to market leader in 'real world' http://www.inboxrobot.com/news.php?fid=186508396 4 Sep 2008 14:30 GMT ... the first study of its kind, a drug-eluting stent (DES) with a biodegradable polymer applied only ... after the procedure, the numbers of deaths, heart attacks and repeat interventions required because of ... Biosensors DES demonstrates equivalent safety and efficacy to industry leading DES http://www.inboxrobot.com/news.php?fid=186421111 4 Sep 2008 04:26 GMT ... "Company", BIG:SP) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety ... such as conventional DES, bare-metal stents and open-heart surgery. It has three separate drug-eluting stent ... Study: Bypass Better Than Stents in Long Term http://www.inboxrobot.com/news.php?fid=186390027 3 Sep 2008 23:20 GMT ... Study says bypass surgery for heart patients better than stents in the long term MUNICH, Germany (AP) ... for by Boston Scientific, makers of the drug-coated stent used in the trial. After one ... Stentys Appoints RenA(C) Spaargaren, MD, as Chief Medical Officer http://www.inboxrobot.com/news.php?fid=186302598 3 Sep 2008 13:57 GMT ... PARIS, Sep 03, 2008 (BUSINESS WIRE) -- Stentys ( ) announced today that it has ... Stentys is developing the world's first next-generation drug-eluting stent for treatment of blocked coronary artery ... reducing the blood flow and depriving the heart muscle of oxygen. The dramatic consequence of ... Stentys Appoints Rene Spaargaren, MD, as Chief Medical Officer http://www.inboxrobot.com/news.php?fid=186300272 3 Sep 2008 13:51 GMT ... Spaargaren as its Chief Medical Officer (CMO). Stentys is developing the world's first next-generation drug-eluting stent for treatment of blocked coronary artery ... reducing the blood flow and depriving the heart muscle of oxygen. The dramatic consequence of ... TAXUS OLYMPIA Registry Shows Excellent Outcomes For High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent http://www.inboxrobot.com/news.php?fid=186252407 3 Sep 2008 08:54 GMT ...